CD22 and acute lymphoblastic leukemia: The Alliance A042001 randomized phase II trial (NCT05303792) will investigate whether the experimental arm (InO in combination with mini-hyperCVD) results in superior MRD-negative EFS compared with a control arm of dose-adjusted hyperCVAD in previously untreated adults aged 50 years or older with CD22+ Philadelphia chromosome–negative (Ph-) BCP-ALL.